Additional Nodal Metastasis Nomogram
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۱۴
حداقل ۰ — حداکثر ۷
حداقل ۰ — حداکثر ۹ • واحد: cm
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Very Low Risk0–10
- Low Risk10–20
- Moderate Risk20–50
- High Risk50–100
The Additional Nodal Metastasis Nomogram calculates predicting probability of additional non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy. Key inputs include nuclear grade. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Predicts probability of additional non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy
Clinical Indication
The Additional Nodal Metastasis Nomogram is indicated for bedside clinical practice to support Predicts probability of additional non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
Linear predictor = β₀ + β₁(nuclear grade) + β₂(LVI) + β₃(multifocal) + β₄(ER status) + β₅(negative SLNs) + β₆(positive SLNs) + β₇(pathologic size) + β₈(detection method). Probability = exp(linear predictor) / (1 + exp(linear predictor))
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| nuclear_grade | string | Yes | Nuclear grade and tumor type |
| lymphovascular_invasion | string | Yes | Presence of lymphovascular invasion (LVI) |
| multifocal | string | Yes | Multifocal tumor (cancer in multiple locations in breast) |
| estrogen_receptor_status | string | Yes | Estrogen receptor (ER) status |
| negative_slns | integer | Yes | Number of negative sentinel lymph nodes |
| positive_slns | integer | Yes | Number of positive sentinel lymph nodes |
| pathologic_size | float | Yes | Pathologic size of tumor in centimeters(cm) |
| detection_method | string | Yes | Method of detection of sentinel lymph node metastases |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–10 | Very Low Risk | Very low probability |
| 10–20 | Low Risk | Low probability |
| 20–50 | Moderate Risk | Moderate probability |
| 50–100 | High Risk | High probability |
Evidence-Based References (EBM)
- Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Fey JV, Tan LK, Borgen PI, Cody HS 3rd, Kattan MW. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003 Dec;10(10):1140-51.
- Specht MC, Kattan MW, Gonen M, Fey J, Van Zee KJ. Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann Surg Oncol. 2005 Aug;12(8):654-9.